Sherbrooke Park Advisers’s Recursion Pharmaceuticals RXRX Stock Holding History

Sherbrooke Park Advisers’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	$57.7K	Sell	14,101 -15,583	-52%	-$77.2K	0.15%	159
2025 Q3	$145K	Buy	29,684 +18,328	+161%	+$96.3K	0.07%	419
2025 Q2	$57.5K	Buy	+11,356	New	+$55.8K	0.03%	493
2025 Q1	–	Sell	-26,230	Closed	-$177K	–	890
2024 Q4	$177K	Buy	+26,230	New	+$176K	0.06%	611
2024 Q3	–	Sell	-33,458	Closed	-$251K	–	1215
2024 Q2	$251K	Buy	+33,458	New	+$292K	0.04%	695

Other funds holding RXRX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sherbrooke Park Advisers's RXRX Position: Q4 2025 in Review

Sherbrooke Park Advisers reduced its Recursion Pharmaceuticals (RXRX) stake by 52% in Q4 2025, selling an estimated $77.2K and leaving 14,101 shares worth $57.7K. The position accounts for 0.15% of the portfolio, ranked #159.

Sherbrooke Park Advisers first reported a position in RXRX in Q2 2024 and has held it in 5 quarters since. The position peaked at $251K in Q2 2024. 333 funds tracked by Wall St. Rank hold RXRX as of Q4 2025.

Sherbrooke Park Advisers held 14,101 shares of Recursion Pharmaceuticals worth $57.7K as of Q4 2025.
Sherbrooke Park Advisers sold 15,583 Recursion Pharmaceuticals shares in Q4 2025, an estimated $77.2K.
Recursion Pharmaceuticals made up 0.15% of Sherbrooke Park Advisers's portfolio in Q4 2025, its #159 holding.
Sherbrooke Park Advisers first reported a position in Recursion Pharmaceuticals in Q2 2024 and has held it in 5 quarters since.
Sherbrooke Park Advisers's Recursion Pharmaceuticals position peaked at $251K in Q2 2024.
333 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q4 2025.

Based on Sherbrooke Park Advisers's 13F filing for Q4 2025, filed 17 Feb 2026.